Table 1.
Recent trials on neoadjuvant chemotherapy, resectability, and outcomes.
| Study | Design | Local stage | Chemotherapy | n | Resectability | R0 rate | Median os (months) |
|---|---|---|---|---|---|---|---|
| McKenzie 2013 | Phase 2 trial | Res | Gem/nP | 25 | 80.0% | 95% | NA |
| O'Reilly 2014 | Phase 2 trial | Res | Gem/oxaliplatin | 38 | 71.0% | 74% | 27.2 |
| Sliesoraitis 2014 | Phase 2 trial | Res/BR | Gem/nP VS surgery | 32 (10 VS 22) | 80% VS 100% | 60% VS 77% | NA |
| lelpo 2016 | Phase2 trial | Res/BR | Gem/nP | 25 | 68.0% | 100% | 21 |
| Katz 2016 | Phase 1/2 trial | BR | mFOLFIRINOX | 22 | 68.0% | 93% | 21.7 |
| Okada 2017 | Phase 1 trial | BR | Gem/nP | 10 | 80.0% | 70% | NA |
| Tsai 2018 | Phase 2 trial | Res/BR | 5-FU or gemcitabine-based chemotherapy,depending on molecular profiling | 130 | 82.0% | 81% | 38 |
| Reni 2018 | Phase 2/3 trial | BR/LA | Gem/nP VS Gem/nP/cis/cap | 54 (28 VS 26) | 32% VS 31% | NA | |
| Murphy 2018 | Phase2 trial | BR | FOLFIRINOX+CRT | 48 | 66.6% | 97% | 37.7 |
| De Marsh 2018 | Phase2 trial | Res | FOLFIRINOX | 21 | 81.0% | 94% | 34 |
| Wei 2019 | Phase2 trial | Res | Gem/erlotinib | 114 | 73.0% | 81% | 21.3 |
| Barbour 2020 | Phase2 trial | Res | Gem/nP | 42 | 71.4% | 86% | 23.5 |
| Sohal 2020 | Phase2 trial | Res | FOLFIRINOX VS Gem/nP | 55 VS 47 | 73%VS 70% | 85%VS 85% | 22.4 VS 23.6 |
Gem, gemcitabine; nP, nab-paclitaxel; CRT, chemoradiation therapy; OS, overall survival; Res, resectable; BR, borderline resectable.